Ad
related to: donepezil worsening dementia in the elderly
Search results
Results from the WOW.Com Content Network
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3] [4] [8] It appears to result in a small benefit in mental function and ability to function. [9] Use, however, has not been shown to change the progression of the disease. [10] Treatment should be stopped if no benefit ...
Dementia with Lewy bodies (DLB) is a type of dementia, a group of diseases involving progressive neurodegeneration of the central nervous system. [11] It is one of the two Lewy body dementias, along with Parkinson's disease dementia. [12] Dementia with Lewy bodies can be classified in other ways.
Donepezil, which belongs to a class of medication called acetylcholinesterase inhibitors, is most commonly used to treat dementia in patients with Alzheimer's disease. Although it cannot cure Alzheimer's, it can provide patients with a better quality of life by inhibiting the loss of function and improving the ability to think. [ 20 ]
It's possible that sundowning in dementia patients is caused by a combination of hormonal changes, brain deterioration or damage that has occurred, environmental factors, disruption to a person's ...
A RAND Corporation study pinpointed several unexpected predictors at age 60 that will likely lead to dementia later on. Researcher Peter Hudomiet and expert Dr. Marcie Smith discuss the health ...
Here’s what you need to know to manage dementia. While sundowning can happen at any stage of dementia, it’s more common during the middle and later stages. Here’s what you need to know to ...
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor. [1] It is taken by mouth. [1]
Paraoxon and rivastigmine are both acetylcholinesterase inhibitors and butyrylcholinesterase inhibitors. [14] [11] [7]In 2015, the United States Food and Drug Administration's Adverse Event Reporting System database compared rivastigmine to the other ChEI drugs donepezil and galantamine found that rivastigmine was associated with a higher frequency of reports of death as an adverse event.
Ad
related to: donepezil worsening dementia in the elderly